June 5, 2019
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
• Top-line data is anticipated in the first half of 2020
• If PSOARING trials are successful, a New Drug Application (NDA) filing with the U.S. Food and Drug...
Dermavant is a proud sponsor of
Eczema Awareness Month
Dermavant’s
Robust Pipeline
Dermavant’s medical dermatology pipeline includes product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.
Dermavant Voices:
Patient‑Focused Innovation
Watch the video featuring Todd Zavodnick, CEO, as he talks about transforming patients’ lives and more
